Result Filters
Clinical review report. Dexamethasone (Ozurdex) (Allergan, Inc.) : indication for the treatment of adult patients with diabetic macular edema who are pseudophakic.
- Author(s):
- Canadian Agency for Drugs and Technologies in Health, issuing body
- Title(s):
- Clinical review report. Dexamethasone (Ozurdex) (Allergan, Inc.) : indication for the treatment of adult patients with diabetic macular edema who are pseudophakic.
- Other Title(s):
- Dexamethasone (Ozurdex) (Allergan, Inc.)
- Series:
- CADTH common drug review
- Country of Publication:
- Canada
- Publisher:
- Ottawa (ON) : Canadian Agency for Drugs and Technologies in Health, 2018 Nov.
- Description:
- 1 online resource.
-
Language:
- English
- Electronic Links:
- https://www.ncbi.nlm.nih.gov/books/NBK539255/
- Summary:
- Dexamethasone (Ozurdex) has a Health Canada-approved indication for the treatment of macular edema following central retinal vein occlusion, the treatment of noninfectious uveitis affecting the posterior segment of the eye, and for the treatment of adult patients with diabetic macular edema (DME) who are pseudophakic. The objective of this review is to perform a systematic review of the beneficial and harmful effects of dexamethasone 700 mcg intravitreal injection for the treatment of adults with DME who are pseudophakic.
- MeSH:
- Canada
Dexamethasone/therapeutic use
Diabetic Retinopathy/drug therapy
Macular Edema/drug therapy*
Pseudophakia
Treatment Outcome
- Publication Type(s):
- Review
- Notes:
- Includes bibliographical references.
Funding: CADTH receives funding from Canada's federal, provincial, and territorial governments, with the exception of Quebec.
- Other ID:
- (OCoLC)1162822832
- NLM ID:
- 101747164 [Electronic Resource]